The Aurora Kinases are highly related serine-threonine kinases, essential for accurate and equal segregation of genomic material during mitosis. A large number of studies have linked the aberrant expression of Aurora kinases to cancer, leading to the development of specific Aurora kinases inhibitors. Several small molecules inhibit with a similar efficacy both Aurora A and Aurora B, however, in most cases the effects resemble Aurora B disruption by genetic methods, indicating that Aurora B represents an effective therapeutic target. These drugs are currently under preclinical or clinical evaluation and are reviewed in this article. The relevant patents are discussed.
Aurora a and B kinases--targets of novel anticancer drugs / Libertini, Silvana; Abagnale, Antonella; Passaro, C.; Botta, Ginevra; Portella, Giuseppe. - In: RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY. - ISSN 1574-8928. - STAMPA. - 5:3(2010), pp. 219-241.
Aurora a and B kinases--targets of novel anticancer drugs.
LIBERTINI, SILVANA;ABAGNALE, ANTONELLA;BOTTA, GINEVRA;PORTELLA, GIUSEPPE
2010
Abstract
The Aurora Kinases are highly related serine-threonine kinases, essential for accurate and equal segregation of genomic material during mitosis. A large number of studies have linked the aberrant expression of Aurora kinases to cancer, leading to the development of specific Aurora kinases inhibitors. Several small molecules inhibit with a similar efficacy both Aurora A and Aurora B, however, in most cases the effects resemble Aurora B disruption by genetic methods, indicating that Aurora B represents an effective therapeutic target. These drugs are currently under preclinical or clinical evaluation and are reviewed in this article. The relevant patents are discussed.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
